Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 12, pp 3674–3675 | Cite as

Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases

  • Andres J. YarurEmail author
  • Alexandra Bruss
  • Snehal Naik
  • Poonam Beniwal-Patel
  • Caroline Fox
  • Anjali Jain
  • Brandon Berens
  • Amir Patel
  • Ryan Ungaro
  • Bayda Bahur
  • Marla Dubinsky
  • Daniel J. Stein
Correction
  • 296 Downloads

Correction to: Digestive Diseases and Sciences (2019) 64:1651–1659  https://doi.org/10.1007/s10620-019-05570-1

The original version of the article unfortunately contained a couple of errors. In ‘Methods’ section, ‘Outcomes’ subsection, the sentence ‘Endoscopic remission was defined as an SESCD ≤ 2 in patients with CD and an EMS ≤ 2 in UC patients while off corticosteroids.’ should read ‘Endoscopic remission was defined as an SES-CD ≤ 2 in patients with CD and an EMS ≤ 1 in UC patients while off corticosteroids.’

In Figure 1, legend of light blue coloured bars ‘In Endoscopic Remission at Week 52’ should be replaced with ‘Not in Endoscopic Remission at Week 52’. Corrected version of Fig. 1 is given below.
Fig. 1

Differences between vedolizumab levels at several time points among patients that were and were not in remission at week 52 of therapy. Endoscopic remission was defined as mucosal healing, clinical remission, and normal C-reactive protein

Notes

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Andres J. Yarur
    • 1
    Email author
  • Alexandra Bruss
    • 2
  • Snehal Naik
    • 3
  • Poonam Beniwal-Patel
    • 1
  • Caroline Fox
    • 1
  • Anjali Jain
    • 3
  • Brandon Berens
    • 2
  • Amir Patel
    • 1
  • Ryan Ungaro
    • 4
  • Bayda Bahur
    • 3
  • Marla Dubinsky
    • 4
  • Daniel J. Stein
    • 1
  1. 1.Division of Gastroenterology and HepatologyMedical College of Wisconsin, Hub for Collaborative MedicineMilwaukeeUSA
  2. 2.Clinical Translational Science InstituteMedical College of WisconsinMilwaukeeUSA
  3. 3.Prometheus Laboratories IncSan DiegoUSA
  4. 4.Icahn School of MedicineMount Sinai HospitalNew YorkUSA

Personalised recommendations